Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover

Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Breast Cancer Res Treat
Prif Awduron: Oesterreich, Steffi, Henry, N. Lynn, Kidwell, Kelley M., Van Poznak, Catherine H., Skaar, Todd C., Dantzer, Jessica, Li, Lang, Hangartner, Thomas N., Peacock, Munro, Nguyen, Anne T., Rae, James M., Desta, Zeruesenay, Philips, Santosh, Storniolo, Anna M., Stearns, Vered, Hayes, Daniel F., Flockhart, David A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4807610/
https://ncbi.nlm.nih.gov/pubmed/26536870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3608-8
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg